Quantum Genomics (Alternext – FR0011648971 – ALQGC), a biopharmaceutical company with the mission of developing new therapies for unmet medical needs in the field of cardiovascular diseases, today announced positive top-line results from its Phase IIa trial of lead candidate QGC001 in patients with hypertension (high blood pressure).
[button link=”http://www.quantum-genomics.com/www/wp-content/uploads/2016/09/QUANTUM_PR_QGC001-Phase-IIa-results_20160929_EN_FV3.pdf” target=”_blank” title=”Download Press Release” size=”small” color=”red”]
